Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Trial
Official title:
Managed Access Programs for LNP023, Iptacopan
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
- CLNP023B12004M - Available - Managed Access Program (MAP) Cohort Treatment Plan CLNP023B12004M to Provide Access to Iptacopan (LNP023) for Complement 3 Glomerulopathy in Native and Transplanted Kidneys. - CLNP023N12001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CLNP023N12001M to provide access to Iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
| Terminated |
NCT05116787 -
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
|
Phase 2 | |
| Recruiting |
NCT06294301 -
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
|
Phase 1 | |
| Completed |
NCT03472885 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
|
Phase 2 | |
| Completed |
NCT03946748 -
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Enrolling by invitation |
NCT03427060 -
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
|
Phase 2 | |
| Completed |
NCT03078582 -
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
|
Phase 2 | |
| Completed |
NCT03053102 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Not yet recruiting |
NCT06312644 -
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
|
||
| Completed |
NCT03588026 -
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
|
Phase 3 | |
| Completed |
NCT03056040 -
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
|
Phase 3 | |
| Completed |
NCT00145613 -
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00587054 -
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
|
Phase 2 | |
| Recruiting |
NCT05876312 -
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
|
Phase 1 | |
| Completed |
NCT04820530 -
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
|
Phase 3 | |
| Terminated |
NCT03225287 -
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
|
Phase 2 | |
| Completed |
NCT04558918 -
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
|
Phase 3 | |
| Completed |
NCT02352493 -
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04901936 -
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Completed |
NCT02264639 -
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
|
Phase 1 |